Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coya Therapeutics, Inc. - Common Stock (NQ: COYA ) 6.450 -0.310 (-4.59%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Coya Therapeutics, Inc. - Common Stock < Previous 1 2 3 4 5 Next > Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023 August 03, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) July 19, 2023 From Coya Therapeutics, Inc. Via Business Wire Analyst Expectations for Coya Therapeutics's Future July 17, 2023 Via Benzinga Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation July 17, 2023 Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients Via Benzinga The Latest Analyst Ratings for Coya Therapeutics June 08, 2023 Via Benzinga Coya Therapeutics: Another Sucess May 16, 2023 The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company. Via Talk Markets Why Coya Therapeutics Shares Are Shooting Higher Today May 16, 2023 Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in Via Benzinga Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease July 17, 2023 From Coya Therapeutics, Inc. Via Business Wire The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth July 12, 2023 Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this... Via Benzinga Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner July 05, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC) June 28, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD) June 20, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs June 14, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders June 12, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease June 08, 2023 Via Get News Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday June 08, 2023 Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close... Via Benzinga Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation June 07, 2023 Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session June 07, 2023 Via Benzinga Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD) June 07, 2023 From Coya Therapeutics, Inc. Via Business Wire Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket June 06, 2023 Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday June 06, 2023 It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! Via InvestorPlace Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD) June 05, 2023 From Coya Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's After-Market Session June 01, 2023 Via Benzinga Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023 May 22, 2023 From Coya Therapeutics, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 May 18, 2023 Via Benzinga Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today May 16, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 16, 2023 Via Benzinga Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease May 16, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results May 10, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET May 09, 2023 From Coya Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.